Telitacicept group:None

4 trials

Sponsors

The Second Hospital of Shanxi Medical University, The First Affiliated Hospital of China Medical University, Shenyang, China, Shandong Provincial Qianfoshan Hospital, Children's Hospital,Zhejiang University School of Medicine

Conditions

IgA nephropathyIgA vasculitis nephritisMyasthenia gravissystemic lupus erythematosus

Phase 4

A Study on the Efficacy and Safety of Telitacicept for Injection in the Treatment of Generalized Myasthenia Gravis with Positive Anti-Acetylcholine Receptor Antibodies

Active, not recruitingChiCTR2500109279

The First Affiliated Hospital of China Medical University, Shenyang, ChinaMyasthenia gravis

Start: 2025-09-16Updated: 2025-09-22

Comparing Efficacy and Safety of Telitacicept and Belimumab in Systemic Lupus Erythematosus: A Retrospective Multicenter Cohort Study

Active, not recruitingChiCTR2500110784

Shandong Provincial Qianfoshan Hospitalsystemic lupus erythematosus

Start: 2025-11-30Updated: 2025-10-27

Unknown Phase

Efficacy and safety of telitacicept in the treatment of primary IgA nephropathy: a prospective cohort study

Active, not recruitingChiCTR2400083991

The Second Hospital of Shanxi Medical UniversityIgA nephropathy

Start: 2024-05-13Updated: 2024-05-13

The efficacy and safety of telitacicept in children with IgA vasculitis nephritis:A multicenter retrospective study

RecruitingChiCTR2600116591

Children's Hospital,Zhejiang University School of MedicineIgA vasculitis nephritis

Start: 2026-01-12Updated: 2026-01-27